CIRC(01763): The new production line for the second phase of Wuhan Gaoke Technetium-labeled drug has obtained the production license for radiopharmaceuticals.

CIRC (01763) announced that on November 11, 2024, its controlling subsidiary, Wuhan Atomic High-Tech Medicine Co., Ltd. (hereinafter referred to as Wuhan High-Tech), obtained the radioisotope pharmaceutical production permit for the second phase new production line for technetium-labeled drugs. The second phase production line of technetium-labeled drugs in Wuhan High-Tech has added Technetium [99m Tc] Etilelphilin Injection, further enriching the category of radioactive drugs to meet market demands. At the same time, the commissioning of the second phase production line has further enhanced the production capacity of Wuhan High-Tech, improved its market competitiveness, and positively impacted its future production, operation, and profit growth. In the future, the company will continue to enrich the product range of radioactive drugs in its subsidiaries, strengthen the production capacity of its subsidiaries, continuously improve the quality management system, focus on providing high-quality drugs to customers, and empower high-quality development of the company. Meanwhile, the company will continue to serve the "Healthy China" strategy, actively benefiting the general public.